Enzo Biochem, Inc. (ENZB) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enzo Biochem, Inc. (ENZB) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0.
Zuletzt analysiert: 15. März 2026Enzo Biochem, Inc. (ENZB) Gesundheitswesen & Pipeline-Uebersicht
Enzo Biochem, Inc. is an integrated healthcare company specializing in diagnostics, clinical lab services, and life sciences. The company develops and markets diagnostic and research products, operating through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics, serving researchers and clinicians in the United States and internationally.
Investmentthese
Enzo Biochem, Inc. presents a speculative investment opportunity within the diagnostics and life sciences sector. The company's integrated business model, encompassing life sciences products, clinical laboratory services, and therapeutics, offers diversified revenue streams. However, the company's negative P/E ratio of -4.76 and a negative profit margin of -38.6% indicate financial challenges. Potential catalysts include advancements in its therapeutics segment and expansion of its clinical laboratory services. Investors should carefully consider the risks associated with the company's financial performance and OTC market listing. As of 2026-03-15, the company's market capitalization is $0.04 billion.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Enzo Biochem operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
- The company's gross margin stands at 44.1%, indicating a reasonable level of profitability in its core operations.
- Enzo Biochem has a network of 30 patient service centers in New York and New Jersey, providing a regional presence for its clinical laboratory services.
- The company's market capitalization is $0.04 billion as of 2026-03-15.
- Enzo Biochem's stock trades on the OTC market, which may present liquidity and regulatory considerations.
Wettbewerber & Vergleichsunternehmen
Staerken
- Integrated business model with diversified revenue streams.
- Proprietary technologies in diagnostics and therapeutics.
- Established network of clinical laboratories and patient service centers.
- Direct sales force and distribution network.
Schwaechen
- Negative profit margin and P/E ratio.
- Reliance on OTC market listing.
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for therapeutic products.
Katalysatoren
- Ongoing: Development of novel therapeutics in gastrointestinal, infectious, ophthalmic, and metabolic diseases.
- Ongoing: Expansion of clinical laboratory services through increased patient service centers.
- Upcoming: Potential strategic partnerships and collaborations with other companies.
- Ongoing: Increased focus on molecular diagnostics and personalized medicine.
- Ongoing: Geographic expansion into new markets outside the United States.
Risiken
- Ongoing: Competition from larger and more established companies.
- Potential: Regulatory changes and healthcare reforms.
- Potential: Patent expirations and intellectual property challenges.
- Ongoing: Economic downturns and reduced healthcare spending.
- Ongoing: Negative profit margin and P/E ratio indicating financial instability.
Wachstumschancen
- Expansion of Clinical Laboratory Services: Enzo Biochem can expand its Clinical Laboratory Services segment by increasing its network of patient service centers and rapid response laboratories. The market for clinical laboratory services is growing due to the increasing demand for diagnostic testing and personalized medicine. Expanding geographically and offering specialized testing services can drive revenue growth. Timeline: Ongoing expansion efforts with potential for increased market penetration by 2028.
- Development of Novel Therapeutics: The Therapeutics segment offers potential for significant growth through the development of novel therapies for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Successful clinical trials and regulatory approvals could lead to substantial revenue streams. Focus on unmet medical needs and strategic partnerships can accelerate the development process. Timeline: Clinical trial milestones expected in the next 3-5 years.
- Strategic Partnerships and Collaborations: Enzo Biochem can pursue strategic partnerships and collaborations with other companies in the diagnostics and life sciences industry. Collaborations can provide access to new technologies, markets, and funding. Partnering with larger companies can enhance Enzo Biochem's credibility and market reach. Timeline: Ongoing efforts to establish strategic alliances with potential partnerships announced within the next 1-2 years.
- Increased Focus on Molecular Diagnostics: The market for molecular diagnostics is growing rapidly due to advancements in genomics and personalized medicine. Enzo Biochem can capitalize on this trend by expanding its portfolio of molecular diagnostic products and services. Investing in research and development and acquiring complementary technologies can strengthen its position in this market. Timeline: Continuous development and launch of new molecular diagnostic products over the next 3-5 years.
- Geographic Expansion: Enzo Biochem can expand its geographic reach by entering new markets outside the United States. International expansion can provide access to new customers and revenue streams. Adapting its products and services to meet the needs of local markets is crucial for success. Timeline: Exploration of international market opportunities with potential entry into select markets by 2027-2028.
Chancen
- Expansion of clinical laboratory services.
- Development of novel therapeutics.
- Strategic partnerships and collaborations.
- Increased focus on molecular diagnostics.
Risiken
- Competition from larger and more established companies.
- Regulatory changes and healthcare reforms.
- Patent expirations and intellectual property challenges.
- Economic downturns and reduced healthcare spending.
Wettbewerbsvorteile
- Proprietary technologies in genetic engineering and molecular biology.
- Integrated business model encompassing diagnostics, clinical lab services, and therapeutics.
- Established network of patient service centers and rapid response laboratories.
- Direct sales force and distribution network.
Ueber ENZB
Founded in 1976 and headquartered in New York City, Enzo Biochem, Inc. has evolved into an integrated diagnostics, clinical lab, and life sciences company. The company operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers, offering proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits. These products support researchers in areas such as cancer, cardiovascular disease, neurological disorders, and infectious diseases. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests, operating a full-service clinical laboratory in Farmingdale, New York, along with a network of patient service centers and rapid response laboratories. The Therapeutics segment focuses on developing novel approaches in areas such as gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem markets its products and services through a direct sales force and a network of distributors in the United States and internationally.
Was das Unternehmen tut
- Researches, develops, manufactures, and markets diagnostic and research products.
- Offers products based on genetic engineering, biotechnology, and molecular biology.
- Provides clinical laboratory services, including molecular and other clinical tests.
- Operates a network of patient service centers and rapid response laboratories.
- Develops novel therapeutic approaches for various diseases.
- Markets products and services through direct sales and distributors.
Geschaeftsmodell
- Develops and sells life science products to research and drug development customers.
- Provides clinical laboratory services to physicians and patients.
- Develops and commercializes therapeutic products.
- Generates revenue through product sales and service fees.
Branchenkontext
Enzo Biochem, Inc. operates within the medical diagnostics and research industry, a sector characterized by technological innovation and increasing demand for advanced diagnostic tools and personalized medicine. The industry is driven by factors such as an aging population, the rising prevalence of chronic diseases, and advancements in molecular diagnostics. Enzo Biochem competes with companies like ACOGF, CSWYY, DMTTF, IGXT, and MDPEF, all of which are vying for market share in various segments of the diagnostics and life sciences market. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products and services.
Wichtige Kunden
- Clinical research institutions
- Drug development companies
- Bioscience research customers
- Physicians
- Patients
Finanzdaten
Chart & Info
Enzo Biochem, Inc. (ENZB) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ENZB verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ENZB.
Kursziele
Wall-Street-Kurszielanalyse fuer ENZB.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ENZB auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Kara Cannon
CEO
Kara Cannon serves as the CEO of Enzo Biochem, Inc. Her background includes experience in the healthcare and life sciences industries. She is responsible for overseeing the company's strategic direction, operations, and financial performance. Her leadership focuses on driving innovation, expanding market reach, and enhancing shareholder value. She manages a team of 125 employees.
Erfolgsbilanz: Since becoming CEO, Kara Cannon has focused on streamlining operations and driving growth in key segments. Her strategic decisions have included expanding the company's clinical laboratory services and investing in the development of novel therapeutics. She has also worked to strengthen the company's financial position and enhance its market presence.
ENZB OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Enzo Biochem, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and speculative investments.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for price volatility and manipulation.
- Liquidity challenges and difficulty in buying or selling shares.
- Higher risk of fraud or mismanagement.
- Limited access to capital and financing.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Review the company's risk factors and potential liabilities.
- Consult with a financial advisor or conduct independent research.
- Understand the risks associated with OTC trading.
- Established history of operations since 1976.
- Presence in the diagnostics, clinical lab, and life sciences industries.
- Network of patient service centers and rapid response laboratories.
- Direct sales force and distribution network.
Was Anleger ueber Enzo Biochem, Inc. (ENZB) wissen wollen
What are the key factors to evaluate for ENZB?
Evaluating ENZB involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Integrated business model with diversified revenue streams.. Primary risk to monitor: Ongoing: Competition from larger and more established companies.. This is not financial advice.
How frequently does ENZB data refresh on this page?
ENZB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ENZB's recent stock price performance?
Recent price movement in Enzo Biochem, Inc. (ENZB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated business model with diversified revenue streams.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ENZB overvalued or undervalued right now?
Determining whether Enzo Biochem, Inc. (ENZB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ENZB?
Before investing in Enzo Biochem, Inc. (ENZB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ENZB to a portfolio?
Potential reasons to consider Enzo Biochem, Inc. (ENZB) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Integrated business model with diversified revenue streams.. Additionally: Proprietary technologies in diagnostics and therapeutics.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ENZB?
Yes, most major brokerages offer fractional shares of Enzo Biochem, Inc. (ENZB) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ENZB's earnings and financial reports?
Enzo Biochem, Inc. (ENZB) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ENZB earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is based on the most recent available information.
- OTC market data may be limited and subject to change.
- AI analysis is pending and may provide additional insights.